CureVac N.V. (NASDAQ: CVAC) experienced a significant stock surge following a favorable decision in a patent dispute. The most recent market check showed that CVAC shares had increased 11.79% to $3.13. The spike comes after the European Patent Office (EPO) declared that CureVac’s European patent EP 3 708 668 B1 was still valid, although with changes to make its protections more clear.
Opposition Dismissed, Patent Maintained
The decision follows a hearing in which BioNTech SE’s arguments were generally rejected by the EPO’s opposition division. In April 2023, BioNTech first challenged the patent’s validity; nevertheless, the EPO’s ruling upheld its standing in a modified version.
As CureVac continues to handle ongoing intellectual property challenges in Germany, this result represents a significant triumph. The six patents at the heart of the dispute between CVAC and BioNTech include the one that was upheld.
Upcoming Infringement Ruling in Germany
In light of this decision, the Düsseldorf Regional Court will have to decide whether BioNTech has violated the updated patent. The date of the infringement hearing is July 1, 2025.
A decision in CureVac’s favor would start the process of determining possible damages. The EPO’s affirmation supports CVAC’s position that the updated patent is still enforceable and has been violated.
The Dedication of CureVac to mRNA Innovation
CureVac sees this court ruling as an important step in getting credit for its work on mRNA vaccine technology. The company has been at the forefront of messenger ribonucleic acid (mRNA) research, producing significant innovations such split poly-A tail technology, which enhances protein synthesis and improves vaccination efficacy.
CureVac’s patented technology works on the basis of using customized mRNA as a data carrier to tell the body to make its own proteins that can combat a variety of ailments. CVAC remains steadfast in its determination to receive fair compensation for its innovations as it advances mRNA-based therapy in the US and European markets.